Amgen , a leading biotechnology company known for developing therapies in oncology, cardiovascular disease, and inflammation, is diving headfirst into the booming obesity drug mar ...

Despite these positive clinical developments, Amgen and Viking Therapeutics have performed poorly on the stock market in the past 12 months, though progress in this area might eventually help them ...

Image source: Getty Images. Amgen's leading weight loss candidate is called MariTide. In November, the biotech reported that in a phase 2 study, the medicine led to an average weight loss of about ...

RBC lowers Amgen price target to $320 but keeps Outperform rating based on steady outlook for MariTide. Goldman sees MariTide efficacy risk in Phase 3 trial due to dose escalation, possibly ...

The company’s latest venture focuses on MariTide, a promising weight loss injection. This injection could substantially boost Amgen’s revenue. MariTide has shown early signs of success.

Amgen's leading weight loss candidate is called MariTide. In November, the biotech reported that in a phase 2 study, the medicine led to an average weight loss of about 20% in overweight or obese ...

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

with management highlighting differentiated profiles for MariTide and Repatha as mitigating factors. Amgen’s Q1 2025 earnings call highlighted strong revenue and volume growth, driven by key ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling participants. The historically tight-lipped Amgen execs remain judicious ...